Corriere della Sera - Imprese - 10 June 2024

In Q1 2024, the health sector's manufacturing company obtained margins in the double digits, surpassing its performance in 2023.

The group's margins for Q1 2024 have surpassed previous records, and the company is on track to meet its ambitious goals, which align with analysts' predictions.

This growth spans all three divisions – nutraceuticals, pharmaceuticals and cosmetics – and is supported by strategic investments to boost production capabilities. This includes enlarging existing (Nutra), and building new facilities (Pharma), and engaging the CDMO in the innovation process to enhance the market competitiveness of its customers.

Read the article for further details.